QURE stock icon

uniQure
QURE

$4.46
1.76%
 

About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Employees: 480

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 7 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 34

10% less funds holding

Funds holding: 141 [Q4 2023] → 127 (-14) [Q1 2024]

17.16% less ownership

Funds ownership: 84.6% [Q4 2023] → 67.44% (-17.16%) [Q1 2024]

25% less call options, than puts

Call options by funds: $5.46M | Put options by funds: $7.26M

38% less capital invested

Capital invested by funds: $274M [Q4 2023] → $170M (-$104M) [Q1 2024]

44% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 32

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$6
35%
upside
Avg. target
$18.43
313%
upside
High target
$30
573%
upside

7 analyst ratings

positive
57%
neutral
43%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
461%upside
$25
Buy
Reiterated
8 May 2024
Mizuho
Uy Ear
35%upside
$6
Neutral
Maintained
8 May 2024
Mizuho
Uy Ear
57%upside
$7
Neutral
Maintained
4 Mar 2024
HC Wainwright & Co.
Patrick Trucchio
461%upside
$25
Buy
Maintained
1 Mar 2024
Goldman Sachs
Salveen Richter
79%upside
$8
Neutral
Downgraded
29 Feb 2024

Financial journalist opinion